{
    "clinical_study": {
        "@rank": "47115", 
        "brief_summary": {
            "textblock": "The objective of this treatment IND protocol is to make didanosine (ddI) available to\n      patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have\n      developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program\n      due to protocol exclusion or geographic location."
        }, 
        "brief_title": "A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "AIDS-Related Complex", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Concomitant medications for the treatment of AIDS or ARC (including aerosolized\n             pentamidine).\n\n          -  Phenytoin, but with caution.\n\n          -  Note:\n\n          -  Extreme caution should be exercised in the use of ddI in any patient receiving\n             concomitant therapies, particularly those receiving other nucleosides (e.g.\n             ganciclovir), drugs with toxicities similar to those observed with ddI (list included\n             under concomitant medications section of protocol), and other drugs with significant\n             toxicities, including many drugs used for treatment of major opportunistic\n             infections.\n\n        Patients must:\n\n        - Have a diagnosis of AIDS or be symptomatic, HIV positive, and have a CD4 cell count <\n        200 cells/mm3.\n\n        Be intolerant to zidovudine (AZT) therapy. Not be suitable for study entry into the phase\n        II didanosine (ddI) study by reason of inclusion or exclusion criteria or by reason of\n        geographic location.\n\n        Be able to provide signed informed consent (parent/guardian as appropriate). Be available\n        for monthly follow-up while taking ddI. Meet baseline lab criteria within 14 days prior to\n        initial drug dosing.\n\n        Note:\n\n          -  Extreme caution should be exercised in the use of ddI in any patient receiving\n             concomitant therapies, particularly those receiving other nucleosides (e.g.,\n             ganciclovir), drugs with toxicities similar to those observed with ddI (list included\n             under concomitant medications section of protocol), and other drugs with significant\n             toxicities, including many drugs used for treatment of major opportunistic\n             infections.\n\n        Caution should also be exercised in a patient having intractable diarrhea or patients\n        following a low-sodium diet.  Physicians caring for patients must perform clinical and\n        laboratory evaluations every 7 - 10 days for the first 2 months of ddI therapy.  All\n        high-risk patients (for example, patients with preexisting disorders of body systems known\n        to be adversely affected by ddI, particularly those with a history of peripheral\n        neuropathy, pancreatitis, seizure disorder, cardiac abnormalities, gout, and significant\n        elevations of liver function test results), must have clinical and laboratory evaluations\n        performed every 10 days and results submitted to Bristol-Myers Squibb on the case report\n        forms provided.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Anti-emetic medication.\n\n          -  Required:\n\n          -  Zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malignancy likely to require chemotherapy in the first 3 months of ddI treatment.\n\n          -  Acute pancreatitis.\n\n          -  A poorly controlled seizure disorder.\n\n          -  Grade B or greater peripheral neuropathy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT).\n\n          -  Chemotherapy in the first 3 months of ddI treatment.\n\n        Patients with the following are excluded:\n\n          -  Malignancy likely to require systemic chemotherapy in the first 3 months of ddI\n             treatment.\n\n          -  Acute pancreatitis.\n\n          -  A poorly controlled seizure disorder.\n\n          -  Grade B or greater peripheral neuropathy.\n\n        Prior Medication:\n\n        Excluded within 15 days of study entry:\n\n          -  Any antiretroviral drug except zidovudine (AZT)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002028", 
            "org_study_id": "040A", 
            "secondary_id": "454-999-001"
        }, 
        "intervention": {
            "intervention_name": "Didanosine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Drugs, Investigational", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "August 15, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Princeton", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "085434500"
                }, 
                "name": "Bristol - Myers Squibb Co"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)", 
        "overall_official": {
            "affiliation": ".", 
            "last_name": ". .", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Groopman J. A phase I study of 2'-3'-dideoxyinosine (ddI) administered orally twice daily to patients with AIDS or ARC and hematologic intolerance to azidothymidine (AZT). Int Conf AIDS. 1990 Jun 20-23;6(3):204 (abstract no SB473)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002028"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2007"
    }, 
    "geocoordinates": {
        "Bristol - Myers Squibb Co": "40.366 -74.679"
    }
}